RheumNow
-
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 09/18/2025 – 14:00 RheumNow Dr. John Cush QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST…
-
CDC 2025–26 Updates to Influenza Vaccination. – Most are trivalent inactivated (IIV3s) or vaccines (RIV3), few live v
CDC 2025–26 Updates to Influenza Vaccination. – Most are trivalent inactivated (IIV3s) or vaccines (RIV3), few live v https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 09/18/2025 – 13:53 RheumNow Dr. John Cush CDC 2025–26 Updates to Influenza Vaccination. – Most are trivalent inactivated (IIV3s) or vaccines (RIV3), few live virus(LAIV3) – FDA approved FluMist (LAIV3) for self-administration (ages 2-49)…
-
Patient Resource: The Hidden Connection – ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about IL
Patient Resource: The Hidden Connection – ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about IL https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 09/18/2025 – 13:00 RheumNow Dr. John Cush Patient Resource: The Hidden Connection – ILD and Rheumatic Disease Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of…
-
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortali
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortali https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 09/18/2025 – 10:18 RheumNow Dr. John Cush RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151…
-
What you need to know about scleroderma-related lung fibrosis
What you need to know about scleroderma-related lung fibrosis khannad@umich.edu Thu, 09/18/2025 – 11:00
-
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Thu, 09/18/2025 – 10:00 RheumNow Dr. John Cush When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD)…
-
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demo
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demo https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 20:00 RheumNow Dr. John Cush STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent…
-
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 18:30 RheumNow Dr. John Cush Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS…
-
Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did no
Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did no https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 17:00 RheumNow Dr. John Cush Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR…
-
🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis &
🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 15:00 RheumNow Dr. John Cush 🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/dmhULfqiMj Created by…
-
GLP-1 drugs cost-effective for knee osteoarthritis and obesity
GLP-1 drugs cost-effective for knee osteoarthritis and obesity jjcush@gmail.com Wed, 09/17/2025 – 14:20
-
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurem
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurem https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 13:00 RheumNow Dr. John Cush SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV…
-
Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient c
Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient c https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 11:30 RheumNow Dr. John Cush Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/5wD1K7J1Gq ILD Treatment and…
-
Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif co
Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif co https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Wed, 09/17/2025 – 10:01 RheumNow Dr. John Cush Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif correlation w/ US synovitis.…
-
Controversies in ILD
Controversies in ILD tammytilley@gm… Wed, 09/17/2025 – 08:25 Education/ACR/EULAR Anti-Rheumatic Rx Novel Rx Other Rheumatoid Arthritis Cardio/Pulmonary Scleroderma/Raynauds This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: Jeffrey Sparks, MD, Janet Pope,…
-
Significant diagnostic and treatment delays
Significant diagnostic and treatment delays gmcdermott@bwh… Wed, 09/17/2025 – 08:00
-
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 20:00 RheumNow Dr. John Cush QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial…
-
How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (esp
How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (esp https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 18:30 RheumNow Dr. John Cush How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory…
-
Controversies in ILD https://t.co/MtbYpDGn1w
Controversies in ILD https://t.co/MtbYpDGn1w https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 19:02 RheumNow Dr. John Cush Controversies in ILD https://t.co/MtbYpDGn1w Dr. John Cush https://x.com/i/broadcasts/1nAKEElWoayKL 16-09-2025
-
August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort a
August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort a https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 17:00 RheumNow Dr. John Cush August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort and expense of maintaining the committee “is no longer justified.”…
-
Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose
Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 15:34 RheumNow Dr. John Cush Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose crisis; they are over 20…
-
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on
RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 14:00 RheumNow Dr. John Cush RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.Are there benefits…
-
Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown
Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 15:00 RheumNow Dr. John Cush Hitting the Target: T2T Therapy in SLE Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of…
-
There is no criteria for infection-induced Antiphospholipid syndr (APS). aPL & aCL abs have been reported w/ COVID,
There is no criteria for infection-induced Antiphospholipid syndr (APS). aPL & aCL abs have been reported w/ COVID, https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 13:00 RheumNow Dr. John Cush There is no criteria for infection-induced Antiphospholipid syndr (APS). aPL & aCL abs have been reported w/ COVID, HCV, HIV, EBV, varicella-zoster, & CMV. infections may induce…
-
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8 https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 09/16/2025 – 11:30 RheumNow Dr. John Cush Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8nnWKbKjk9 (PDF) Standardized Clinical Terms and Definitions for Interstitial Lung Disease… https://buff.ly/viww2Cx 16-09-2025 https://pbs.twimg.com/media/G0-mO9wWMAATPKl.jpg